Subscribe
Share
Share
Embed
Nutricia prizes diet-as-medicine diabetes research, Interaceituna publishes Health Olive findings, Oatly launches Fiber line, and Mondelez acquires Undercover Snacks.
Nutricia just put institutional weight behind Type 2 diabetes remission research — and Oatly is ditching sustainability messaging for functional fiber. Both moves signal where health marketing credibility is heading.
In this episode:
The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.
Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.
Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily
The daily briefing for professionals in health, nutrition, and wellness marketing. Every episode covers an ingredient of the day, the latest science and regulatory updates from EFSA and beyond, and the brand and market moves shaping the nutraceutical industry. Hosted by Klara and Marco — evidence-based, no hype, no bro-science. Built for formulators, brand managers, regulatory affairs teams, and anyone building in the health and nutrition space.
Marco: Four solid stories on the agenda today — a good mix of science and strategy.
Klara: We're starting with prize-winning diabetes research that could hand medical nutrition brands a serious credibility boost.
Marco: Then table olives making a play as a functional food — which is more interesting than it sounds.
Klara: Oatly doubling down on fibre, and Mondelez buying deeper into better-for-you snacking.
Marco: Let's get into it.
Marco: A major nutrition company has just handed the medical nutrition world a significant clinical credibility boost.
Marco: Medical nutrition is a specific category — think dietitian-prescribed products for managing disease, not your average high-street supplement. It sits closer to medicine than wellness. And for years, the evidence base supporting it has been quietly growing. Now it's getting institutional muscle behind it.
Marco: Nutricia — one of Europe's leading medical nutrition companies — has awarded its 2026 Förderpreis, that's its annual research prize, to a study showing that Type 2 diabetes can be pushed into remission through dietary intervention alone. No surgery. No medication changes. Just structured nutritional therapy. That's a striking finding, and Nutricia putting its name and prize behind it signals serious corporate commitment to diet-as-medicine research.
Klara: From a science standpoint, this matters because remission — not just management, but actual remission — of Type 2 diabetes through diet is still a contested area. There's solid evidence it's possible, particularly with very low calorie or low carbohydrate approaches. But the mechanisms, the durability of remission, and which patient profiles respond best are still being worked out. Rewarding this kind of research accelerates that conversation.
Marco: Commercially, this raises the floor for everyone in the nutrition category. When a company like Nutricia backs clinical evidence at this level, it shifts what health professionals and informed consumers expect from nutrition products. General wellness brands that rely on softer claims start looking thinner by comparison.
Klara: And the regulatory point worth making — EFSA authorised health claims don't cover disease treatment. So brands need to be very careful how they translate this kind of research into marketing language. The evidence is compelling. The compliance line is still strict.
Marco: Right, let's move to our next story now.
Klara: Spain's table olive industry has just published research results aimed at turning a pantry staple into a credible functional food ingredient.
Klara: Table olives are already a cornerstone of the Mediterranean diet, which has strong associations with cardiovascular health and longevity. But associations aren't the same as substantiated health claims. To use specific health language on packaging or in marketing across Europe, you need documented evidence — and that evidence base for table olives specifically has been thin.
Klara: Interaceituna, the Spanish industry body representing the table olive sector, has presented findings from its Health Olive project. This was a structured research initiative, executed by scientific institutions, designed to map the nutritional and health properties of table olives. The goal is explicit — build an evidence base that can support health benefit communication in retail, foodservice, and functional food formulations across European markets.
Klara: From a regulatory standpoint, what Interaceituna is doing is smart and necessary. Under EU health claims regulation — EC 1924/2006 — you cannot make a specific health claim on a food product without prior authorisation from EFSA. That authorisation requires robust scientific substantiation. Funding research specifically to generate that substantiation is how serious ingredient players build a credible claim pipeline. The findings haven't translated into EFSA-authorised claims yet, so marketers need to hold back on specific health language until that process plays out.
Marco: Commercially, though, this is well-timed. Consumers are actively moving toward whole-food formats — they want nutrients from food, not just capsules. Table olives sit right in that sweet spot. If the Health Olive findings stack up, you could see olive-based SKUs — that's individual product lines — repositioned with genuine health differentiation across dm, Carrefour, or Holland & Barrett.
Klara: My hesitation is that industry-funded research needs independent replication before it carries real weight. One project from one sector body is a starting point, not a finish line.
Marco: Agreed — and that's actually what makes it interesting to watch. Now, let's move on to our third story.
Marco: Oatly is moving into functional fiber beverages, and it's a signal worth paying close attention to.
Marco: Oatly built its brand on sustainability — oat milk as the planet-friendly dairy swap. That message carried it through enormous growth. But sustainability alone is no longer enough to hold consumer loyalty, particularly when private-label alternatives have closed the quality gap and cost pressures are squeezing margins across the plant-based category.
Marco: During its latest earnings update, Oatly announced a forthcoming Fiber beverage line, positioning functional health benefits — specifically dietary fibre — as its core innovation platform going forward. The timing is deliberate. The brand is absorbing significant cost shocks right now, and rather than competing on price, it's betting that health functionality is the more defensible position.
Klara: From a science angle, fibre is actually one of the more solid grounds to stand on. EFSA has authorised specific health claims for dietary fibre — including contributions to normal bowel function and maintaining normal blood cholesterol levels — provided the product meets defined thresholds. So if Oatly's formulation genuinely delivers meaningful fibre quantities, there's a legitimate claim pathway available. The question I'd want answered is whether this is a substantial functional dose or mostly a marketing dusting.
Marco: That's a fair concern, but commercially, what Oatly brings is reach. Specialist gut-health beverages have existed for years in pharmacy and health channels. When Oatly puts a fibre drink into Carrefour, Lidl, and Sainsbury's, the category reaches an entirely different consumer base. That intensifies shelf competition for every brand already in the gut-health aisle.
Klara: And that competition will force smaller brands to sharpen their science. Which isn't a bad outcome.
Marco: Let's move to our final story now.
Klara: Mondelez has acquired a majority stake in Undercover Snacks, a better-for-you snack brand, as part of its ongoing bolt-on acquisition strategy.
Klara: Legacy confectionery companies have a problem. Their core portfolios are under pressure as consumers shift toward snacks they perceive as healthier. Building credible health brands from scratch takes years. Buying them is faster, cheaper, and comes with an existing consumer base already attached.
Klara: Mondelez — the company behind some of Europe's most recognisable confectionery lines — has now moved on Undercover Snacks, taking a majority stake. This continues a deliberate pattern of acquiring smaller, health-positioned brands rather than developing them internally. For Undercover Snacks, the deal unlocks Mondelez's retail relationships and distribution infrastructure — access that would otherwise take the brand a decade to build organically.
Klara: From a regulatory standpoint, this is where I'd urge caution. Better-for-you is a marketing frame, not a protected term. It tells you nothing about whether a product has substantiated health claims under EC 1924/2006. When a large CPG company absorbs a smaller brand, the pressure to scale quickly can sometimes erode the very ingredient quality or formulation integrity that made the original brand appealing. That's worth watching closely here.
Marco: Commercially, though, this deal is a clear message to every founder-led health snack brand operating in Europe right now. Big CPG is still actively shopping. If you have genuine health positioning and proven shelf performance — whether that's in Boots, Whole Foods, or a strong Amazon ranking — you are a viable acquisition target. That's meaningful for the category.
Klara: Where we'd disagree is on outcomes. Marco sees distribution as pure upside. I think the real test is whether the formulation survives the scale-up. History gives us mixed results on that front.
Marco: That's a fair challenge — and one the industry should keep asking every time one of these deals closes.
Marco: The through-line today is credibility — every brand winning right now is borrowing it from somewhere: clinical trials, ingredient science, or a cleaner acquisition target.
Klara: And borrowed credibility only holds if the underlying evidence does — one weak claim unravels the whole story.